HQL
Tekla Life Sciences Investors
17.70$
+0.0%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +50.8% | +375.7% | +1,009.6% | -97.2% | -3,591.9% | – | -47.1% | -257.2% | – | +268.5% | -0.3% | |
| – | +36.4% | -12.4% | -6.9% | +3.5% | -6.1% | +6.6% | +17.2% | -1.0% | -5.5% | +2.2% | -7.2% | |
| – | – | – | +4,756.4% | -97.0% | -3,591.9% | – | -47.1% | -257.2% | – | +268.5% | -0.3% | |
| – | – | – | -22.8% | – | – | – | -54.6% | +129.4% | -82.6% | – | – | |
| – | +30.2% | -13.5% | -81.0% | +464.1% | -84.3% | -14.3% | +12.3% | +27.6% | -16.1% | +47.5% | -44.2% | |
| – | -55.7% | -65.9% | -90.6% | +345.4% | -79.7% | -9.4% | +12.4% | +16.8% | -13.4% | +18.6% | -43.0% | |
| – | – | – | – | – | – | – | -47.6% | -262.1% | – | +281.6% | +0.3% | |
| – | -51.4% | -82.0% | +791.9% | -55.4% | +109.5% | -100.0% | – | – | – | – | – | |
| – | -54.6% | -129.4% | – | -58.2% | -345.9% | – | -47.6% | -262.1% | – | +281.6% | +0.3% | |
| – | -51.4% | -41.8% | -100.0% | -66.7% | -288,372,700.0% | – | – | – | – | – | – | |
| – | -54.6% | -129.4% | – | -58.2% | -345.9% | – | -47.6% | -262.1% | – | +281.6% | +0.3% | |
| – | -53.0% | -123.4% | – | -11.1% | -215.7% | – | -47.6% | -262.1% | – | +290.2% | -1.9% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.